0
Prokidney Corp Banner Image

Prokidney Corp

  • Ticker PROK
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Prokidney Corp Logo Image
  • 51-200 Employees
  • Based in Winston-Salem, North Carolina
ProKidney (Nasdaq: PROK), a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, REACT™ (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in someMore cases potentially drive meaningful improvement in kidney function. Late-stage CKD, Stage 3b - 4, is a key target for REACT™ therapy. REACT™ has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program, which launched in January 2022.
Prokidney Corp

Most Recent Annual Report

Prokidney Corp
MOST RECENT 2023 Annual Report and Form 10K

Older/Archived Annual Reports

Prokidney Corp Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!